| In millions, except per share items | Jun-30-23 | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 |
| | 8-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A |
| Revenues: |
| Non-US | | 2.1 | 4.9 | | | | | |
| Aytu BioScience | | | | | 7.3 | | | |
| Consumer Health Portfolio | | | | 10.4 | | | | |
| Aytu Women's Health | | | | | | | 0.0 | |
| Other | | 94.6 | 60.7 | 17.2 | | | 3.2 | |
| Total revenues [+] | 107.4 | 96.7 | 65.6 | 27.6 | 7.3 | 3.7 | 3.2 | 2.6 |
| Licensing | | | | | | | | 0.5 |
| Royalties | | | | | | | | 6.1 |
| Products | 107.4 | 96.7 | 65.6 | 27.6 | | 3.7 | 3.2 | |
| Net interest income | | | | | | 0.0 | | |
| Revenue growth [+] | 11.1% | 47.3% | 137.5% | 277.5% | 100.0% | 13.6% | 25.7% | 878.8% |
| Non-US | | -58.3% | | | | | | |
| Aytu | | | | | | | 23.9% | |
| Cost of goods sold | 40.8 | 44.4 | 36.4 | 8.3 | 2.2 | 2.1 | 1.4 | 1.0 |
| Gross profit | 66.6 | 52.3 | 29.2 | 19.4 | 5.1 | 1.6 | 1.8 | 1.6 |
| Gross margin | 62.0% | 54.1% | 44.5% | 70.0% | 69.9% | 44.0% | 56.0% | 62.6% |
| Selling, general and administrative [+] | 70.1 | 69.9 | 55.8 | 31.1 | 18.9 | 17.7 | 17.4 | 8.5 |
| Sales and marketing | 41.4 | 38.7 | 30.3 | 11.4 | | | | |
| General and administrative [+] | 28.6 | 31.2 | 25.5 | 19.7 | | | | |
| General and administrative expenses | 28.6 | 31.2 | 25.5 | 19.7 | | | | |
| Research and development | 4.1 | 14.4 | 5.6 | 1.7 | 0.6 | 0.2 | 1.0 | |
| Other operating expenses | 4.7 | | | | 0.4 | -2.6 | 0.8 | 6.6 |
| EBITDA [+] | -12.3 | -25.9 | -29.0 | -12.2 | -14.1 | -12.7 | -14.7 | -13.3 |
| EBITDA growth | -52.6% | -11.0% | 137.9% | -13.5% | 11.2% | -13.7% | 10.3% | 94.6% |
| EBITDA margin | -11.4% | -26.7% | -44.2% | -44.2% | -192.9% | -347.0% | -456.6% | -520.2% |
| Depreciation | | 6.2 | 3.2 | 1.2 | 0.6 | 1.0 | 2.7 | 0.2 |
| EBITA | -12.3 | -32.0 | -32.2 | -13.4 | -14.7 | -13.7 | -17.4 | -13.5 |
| EBITA margin | -11.4% | -33.1% | -49.1% | -48.6% | -201.0% | -375.3% | -539.0% | -528.4% |
| Amortization of intangibles | 4.8 | 4.1 | 6.0 | 4.5 | 2.1 | 1.6 | 1.7 | 0.7 |
| EBIT [+] | -17.1 | -36.1 | -38.2 | -17.9 | -16.8 | -15.3 | -19.1 | -14.2 |
| EBIT growth | -52.8% | -5.6% | 113.4% | 6.4% | 10.2% | -19.8% | 34.3% | 103.8% |
| EBIT margin | -15.9% | -37.3% | -58.3% | -64.9% | -230.1% | -417.8% | -592.0% | -554.3% |
| Non-recurring items [+] | | 75.5 | 20.6 | 3.2 | | 4.4 | 1.1 | 7.5 |
| Asset impairment | | 75.5 | 12.8 | 0.2 | | 1.9 | 1.3 | 7.5 |
| Interest expense | | | | | 0.5 | 0.7 | 2.5 | |
| Interest expense | | 0.9 | | | 0.5 | 0.7 | 2.5 | |
| Other income (expense), net [+] | | 2.2 | 0.8 | 7.5 | -9.7 | 10.3 | 0.2 | -6.5 |
| Gain (loss) on investments | | | | | | | -0.1 | |
| Gain (loss) on debt retirement | | 0.2 | -1.6 | -0.3 | | | | |
| Gain (loss) on derivative instruments | | 0.2 | | 0.0 | 0.1 | 6.3 | 0.2 | |
| Change in value of contingent liability | | | | 10.4 | | | | |
| Other | | -0.9 | -2.1 | -2.6 | | 4.0 | | -5.5 |
| Pre-tax income | -17.1 | -110.3 | -58.0 | -13.6 | -27.1 | -10.2 | -22.5 | -28.2 |
| Income taxes | 0.0 | -0.1 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.1% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -17.1 | -110.2 | -58.3 | -13.6 | -27.1 | -10.2 | -22.5 | -28.2 |
| Net margin | -15.9% | -114.0% | -88.8% | -49.3% | -370.6% | -278.3% | -698.7% | -1099.7% |
| |
| Basic EPS [+] | ($5.11) | ($3.75) | ($3.48) | ($3.01) | ($3.48) | ($15.31) | ($48.30) | |
| Growth | 36.2% | 7.7% | 15.5% | -13.4% | -77.3% | -68.3% | | |
| Diluted EPS [+] | ($5.11) | ($3.75) | ($3.48) | ($3.01) | ($3.48) | ($15.31) | ($48.30) | |
| Growth | 36.2% | 7.7% | 15.5% | -13.4% | -77.3% | -68.3% | | |
| |
| Shares outstanding (basic) [+] | 3.3 | 29.4 | 16.7 | 4.5 | 7.8 | 0.7 | 0.5 | |
| Growth | -88.6% | 75.5% | 270.6% | -42.0% | 1071.0% | 42.8% | | |
| Shares outstanding (diluted) [+] | 3.3 | 29.4 | 16.7 | 4.5 | 7.8 | 0.7 | 0.5 | |
| Growth | -88.6% | 75.5% | 270.6% | -42.0% | 1071.0% | 42.8% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |